Document And Entity Information - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 02, 2026 |
Jun. 30, 2025 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Amendment Flag | false | ||
| Trading Symbol | GLUE | ||
| Entity Registrant Name | Monte Rosa Therapeutics, Inc. | ||
| Entity Central Index Key | 0001826457 | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Well-known Seasoned Issuer | Yes | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Fiscal Year Focus | 2025 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Shell Company | false | ||
| Document Fiscal Period Focus | FY | ||
| Entity Public Float | $ 212 | ||
| Entity Common Stock, Shares Outstanding | 80,015,667 | ||
| Entity Ex Transition Period | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Entity File Number | 001-40522 | ||
| Entity Tax Identification Number | 84-3766197 | ||
| Entity Address, Address Line One | 321 Harrison Avenue | ||
| Entity Address, Address Line Two | Suite 900 | ||
| Entity Address, City or Town | Boston | ||
| Entity Address, State or Province | MA | ||
| Entity Address, Postal Zip Code | 02118 | ||
| City Area Code | 617 | ||
| Local Phone Number | 949-2643 | ||
| Entity Interactive Data Current | Yes | ||
| Title of 12(b) Security | Common stock, par value $0.0001 per share | ||
| Security Exchange Name | NASDAQ | ||
| Entity Incorporation, State or Country Code | DE | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Documents Incorporated by Reference | Portions of registrant's definitive proxy statement for its annual meeting of shareholders to be filed within 120 days after the close of the registrant's fiscal year are incorporated by reference to into Part III of this annual report on Form 10-K. |
||
| Document Financial Statement Error Correction [Flag] | false | ||
| Auditor Name | Deloitte & Touche LLP | ||
| Auditor Location | Boston, Massachusetts | ||
| Auditor Firm ID | 34 | ||
| Auditor Opinion | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Monte Rosa Therapeutics, Inc. and subsidiaries (the "Company") as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows, for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. |